These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 30753227)
1. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227 [TBL] [Abstract][Full Text] [Related]
2. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M; Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542 [TBL] [Abstract][Full Text] [Related]
4. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study. Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558 [TBL] [Abstract][Full Text] [Related]
5. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622 [TBL] [Abstract][Full Text] [Related]
6. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973 [TBL] [Abstract][Full Text] [Related]
7. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496 [TBL] [Abstract][Full Text] [Related]
8. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
9. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends. Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389 [TBL] [Abstract][Full Text] [Related]
10. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Beyer-Westendorf J; Gelbricht V; Förster K; Ebertz F; Röllig D; Schreier T; Tittl L; Thieme C; Hänsel U; Köhler C; Werth S; Kuhlisch E; Stange T; Röder I; Weiss N Br J Clin Pharmacol; 2014 Oct; 78(4):908-17. PubMed ID: 24697922 [TBL] [Abstract][Full Text] [Related]
11. Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II. Oh S; Kim JS; Oh YS; Shin DG; Pak HN; Hwang GS; Choi KJ; Kim JB; Lee MY; Park HW; Kim DK; Jin ES; Park J; Oh IY; Shin DH; Park HS; Kim JH; Kim NH; Ahn MS; Seo BJ; Kim YJ; Kang S; Lee J; Kim YH J Korean Med Sci; 2018 Dec; 33(49):e323. PubMed ID: 30505257 [TBL] [Abstract][Full Text] [Related]
12. Group-based Trajectory Models to Assess Quality of INR Control and Its Association With Clinical Outcomes. García-Sempere A; Hurtado I; Bejarano D; Santa-Ana Y; Rodríguez-Bernal C; Peiró S; Sanfélix-Gimeno G Med Care; 2020 Apr; 58(4):e23-e30. PubMed ID: 31764479 [TBL] [Abstract][Full Text] [Related]
13. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928 [TBL] [Abstract][Full Text] [Related]
14. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study. Hohnloser SH; Basic E; Nabauer M Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220 [TBL] [Abstract][Full Text] [Related]
15. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK; PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741 [TBL] [Abstract][Full Text] [Related]
16. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials. Carmo J; Ferreira J; Costa F; Carmo P; Cavaco D; Carvalho S; Morgado F; Adragão P; Mendes M Int J Cardiol; 2017 Oct; 244():196-201. PubMed ID: 28679480 [TBL] [Abstract][Full Text] [Related]
17. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086 [TBL] [Abstract][Full Text] [Related]
18. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. Rivera-Caravaca JM; Badimón L; Ferreira-Gonzalez I; Gómez-Doblas JJ; Roca-Luque I; Lekuona I; Jiménez-Candil J; Rodríguez-Padial L; González-Juanatey C; Calvo-Jambrina R; Fácila L; Ruiz-Ortiz M; Anguita M; Marín F Europace; 2022 Jan; 24(1):4-11. PubMed ID: 34115857 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. Zulkifly H; Cheli P; Lutchman I; Bai Y; Lip GYH; Lane DA Thromb Res; 2020 Aug; 192():12-20. PubMed ID: 32416364 [TBL] [Abstract][Full Text] [Related]
20. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants. Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]